LOGIN  |  REGISTER
Recursion

Guardant Health to Participate in Upcoming Investor Conferences

May 08, 2025 | Last Trade: US$37.05 0.04 -0.11

PALO ALTO, Calif. / May 08, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

  • BofA Securities 2025 Healthcare Conference in Las Vegas, NV
    Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time
  • Jefferies Global Healthcare Conference in New York, NY
    Fireside chat on Wednesday, June 4th at 2:35 p.m. Eastern Time
  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL
    Fireside chat on Monday, June 9th at 10:00 a.m. Eastern Time

Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page